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Summary
Pseudoachondroplasia and multiple epiphyseal dysplasia
are genetic skeletal diseases resulting from mutations in
cartilage structural proteins. Electron microscopy and
immunohistochemistry previously showed that the
appearance of the cartilage extracellular matrix (ECM) in
targeted mouse models of these diseases is disrupted;
however, the precise changes in ECM organization and the
pathological consequences remain unknown. Our aim was to
determine the effects of matrilin-3 and COMP mutations on
the composition and extractability of ECM components to
inform how these detrimental changes might influence
cartilage organization and degeneration.
Cartilage was sequentially extracted using increasing
denaturants and the extraction profiles of specific proteins
determined using SDS-PAGE/Western blotting. Furthermore,
the relative composition of protein pools was determined using
mass spectrometry for a non-biased semi-quantitative
analysis.
Western blotting revealed changes in the extraction of
matrilins, COMP and collagen IX in mutant cartilage. Mass
spectrometry confirmed quantitative changes in the extraction
of structural and non-structural ECM proteins, including
proteins with roles in cellular processes such as protein folding
and trafficking. In particular, genotype-specific differences in
the extraction of collagens XII and XIV and tenascins C and X
were identified; interestingly, increased expression of several
of these genes has recently been implicated in susceptibility
and/or progression of murine osteoarthritis.
We demonstrated that mutation of matrilin-3 and COMP
caused changes in the extractability of other cartilage proteins
and that proteomic analyses of Matn3 V194D, Comp T585M
and Comp DelD469 mouse models revealed both common and
discrete disease signatures that provide novel insight into
skeletal disease mechanisms and cartilage degradation.
 2013. Published by TheCompany of Biologists Ltd. This is an
Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/
licenses/by/3.0), which permits unrestricted use, distribution
and reproduction in any medium provided that the original
work is properly attributed.
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Introduction
The chondrodysplasias are a diverse group of many different
phenotypes that arise when endochondral bone growth is
disrupted and include two clinically related phenotypes;
multiple epiphyseal dysplasia (MED) and pseudoachondroplasia
(PSACH) (Warman et al., 2011). MED is genetically
heterogeneous and can be caused by mutations in genes
encoding the extracellular matrix (ECM) proteins matrilin-3,
type IX collagen and cartilage oligomeric matrix protein (COMP)
(Briggs and Chapman, 2002; Jackson et al., 2012); PSACH
results exclusively from COMP mutations (Jackson et al., 2012)
and is more severe than MED, but both phenotypes comprise a
disease spectrum with symptoms that can include joint pain and
stiffness, lower-limb deformities and early onset osteoarthritis
(Briggs and Chapman, 2002).
We have previously generated targeted mouse models of
PSACH-MED with mutations in matrilin-3 (moderate MED:
Matn3 V194D) and COMP (mild PSACH: Comp T585M and
severe PSACH: Comp DelD469) and described the resulting
phenotypes in detail (Leighton et al., 2007; Piro´g-Garcia et al.,
2007; Suleman et al., 2012). Briefly, all three mice models exhibit
disproportionate short stature due to decreased chondrocyte
proliferation and increased and/or spatially dysregulated
apoptosis in the cartilage growth plate.
Whilst the cellular response to mutant matrilin-3 and COMP
expression has been documented in detail (Bell et al., 2012;
Leighton et al., 2007; Piro´g-Garcia et al., 2007; Suleman et al.,
2012), the effects of these mutant proteins on the organisation
and composition of the cartilage ECM are not clearly defined.
Immunohistochemical (IHC) analysis has previously identified
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differences in the staining pattern for matrilin-3, COMP and type
IX collagen in the ECM of mutant growth plates (Leighton et al.,
2007; Piro´g-Garcia et al., 2007; Suleman et al., 2012), whilst the
appearance of the ECM ultra-structure is also different in all three
mutant mice. For example, the collagen fibrils in the inter-
territorial matrix were more clearly visible by electron
microscopy (EM) suggesting that lower levels of fibril surface-
associated proteins were decorating individual collagen fibrils
(Leighton et al., 2007; Piro´g-Garcia et al., 2007; Suleman et al.,
2012). Similar changes to the organisation of the cartilage
pericellular matrix in mice expressing a COMP DelD469
transgene were also noted by EM and IHC (Schmitz et al.,
2008). Furthermore, recent studies demonstrated that a secreted
variant of COMP carrying a MED-mutation in the C-terminal
domain (p.H587R) disrupted collagen fibrillogenesis in vitro and
also in a cell culture model (Hansen et al., 2011). In contrast,
COMP-null mice show no differences in collagen fibril diameter
(Svensson et al., 2002) and these data therefore suggest that
PSACH and MED-causing mutations in matrilin-3 and COMP
can cause changes in the ultra-structure of the cartilage ECM
through antimorphic mechanisms. However, the extent to which
these changes compromise the organisation and function of the
ECM, and therefore contribute to disease pathology and cartilage
degradation, remain to be determined.
The unique biochemical properties of cartilage have made
the study of its ECM technically difficult relative to other
tissues (Wilson et al., 2009). Recently, however, methods have
been described that allow the reproducible analysis of cartilage
proteins by Western blotting, 2-D gel electrophoresis and
mass spectrometry (MS) (Wilson et al., 2009). However, these
methods have not been employed to study cartilage preparations
from a heterogeneous series of gene-targeted mouse models of
genetic skeletal diseases.
We hypothesised that the expression of mutant matrilin-3
and COMP would induce changes to the extractability of other
cartilage components, which would be indicative of alterations
to the anchoring or associations of individual molecules and the
overall functional properties of the tissue. We tested this
hypothesis by analysing the proteins isolated from sequential
extractions of cartilage from mutant mouse models with
different genotypes. This study describes for the first time the
proteomic characterisation of cartilage from Matn3 V194D,
Comp T585M and Comp DelD469 mutant mice using a
combination of Western blotting and semi-quantitative spectral
counting (mass spectrometry) and identifies both common and
unique disease signatures that also provide insight into
detrimental changes that may predispose to cartilage
degeneration.
Results
A candidate approach reveals the effects of matrilin-3 and
COMP mutations on cartilage protein extractability
In the first instance we used a candidate approach to determine the
extractability of a number of ECM molecules including members
of the matrilin protein family, type IX collagen and decorin, which
are all known to interact with matrilin-3 and COMP (Budde et al.,
2005; Fresquet et al., 2010; Fresquet et al., 2007; Holden et al.,
2001; Mann et al., 2004; Wiberg et al., 2003). Articular and
epiphyseal cartilage from 3-week-old mouse knee joints was
sequentially extracted in a series of three buffers and the extracted
proteins were separated by SDS-PAGE and visualised by Western
blotting. The extraction of decorin appeared consistent between all
genotypes and was present primarily in buffer 3 (Fig. 1); in
contrast, the extraction of matrilins 1–4, type IX collagen and
COMP all showed obvious genotype-specific differences in one or
more of the disease models (Figs 1, 2). Whilst there were
numerous minor changes in protein extractability, particularly
slight differences in oligomeric forms, we chose to concentrate on
the more obvious changes, which we considered would have the
greatest influence on ECM organization.
Matrilin-1 was slightly less extractable from Matn3 V194D
and Comp DelD469 cartilage with buffer 2 and several higher-
order oligomeric forms of matrilin-1 were not extractable from
Matn3 V194D cartilage, but were readily extracted from the
cartilage of all other genotypes (Fig. 1). There was also a
reduction in the amount of matrilin-2 oligomers extracted in
buffers 2 and 3 from Comp T585M and Comp DelD469 cartilage
relative to the control and Matn3 V194D cartilages (Fig. 1). A
decrease in the extraction of matrilin-4 dimers and trimers from
Matn3 V194D cartilage buffer 2 samples was observed compared
to the other genotypes, and an increase in the extraction of some
matrilin-4 oligomers that were slightly smaller in size than full-
Fig. 1. SDS-PAGE and Western blotting show genotype differences in the
extractability of specific cartilage structural proteins. Cartilage from wild
type (WT) and mutant (Matn3 V194D, Comp T585M and Comp DelD469)
mice was extracted in a series of three buffers (Buffer 1, 2 and 3). Proteins were
separated by SDS-PAGE under non-reducing conditions and analyzed by
Western blotting using antibodies specific to decorin, matrilin-1, -2 and -4 and
type IX collagen. Higher-order oligomeric forms of matrilin-1 and smaller
oligomeric forms of matrilin-4 are indicated by arrowheads. Key:615putative
monomers; other putative oligomeric forms of proteins are also indicated
(625dimers,635trimers,6n5undetermined molecular forms); * denotes
differences detected in protein extraction profiles between mice of different
genotypes; kDa5mass in kilo Daltons.
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length trimers was also noted in all three mutant genotypes
relative to the wild type control (Fig. 1).
The most striking difference was that it was not possible to
extract type IX collagen from either wild type or Matn3 V194D
cartilage using any of the buffer conditions, whereas a single
molecular form corresponding in size to full length a1(IX) chain
was readily extractable from both Comp DelD469 and T585M
cartilages using buffers 2 and 3 (Fig. 1). Significantly, these
changes in the extractability of type IX collagen were not the
result of differences in the total levels of this protein since IHC
and microarray analyses have consistently demonstrated
comparable levels in mice of all three mutant genotypes that
are similar to wild type controls (supplementary material Figs S1,
S2) (Leighton et al., 2007; Piro´g-Garcia et al., 2007; Suleman
et al., 2012).
Extractability of matrilin-3 from cartilage is increased in Comp
DelD469 and Comp T585M mice compared with wild type
controls
In agreement with previous studies showing the intracellular
aggregation of mutant matrilin-3 (Bell et al., 2012), we observed
that matrilin-3 was extracted with buffers 1–3 from Matn3 V194D
cartilage as a high molecular weight aggregate under non-reducing
conditions (Fig. 2A). We also noted that a small amount of
matrilin-3 was also extracted with buffer 1 in Comp DelD469 and
Comp T585M cartilages compared to wild type (Fig. 2A, insert).
Furthermore, there were also differences in the molecular forms of
matrilin-3 that were extracted from Comp DelD469 and Comp
T585M cartilages. InComp T585M cartilage two oligomeric forms
of approximately 200 kDa were extracted in near equal quantities,
whilst the smaller of these two forms was entirely absent in Comp
DelD469 cartilage (Fig. 2A, insert). The sizes of these oligomers
suggested that they may represent both intact and a smaller
proteolytically processed matrilin-3 tetramer. There were no
discrete oligomers present in Matn3 V194D cartilage.
Extractability of COMP is increased in Matn3 V194D, Comp
DelD469 and Comp T585M mice compared with controls
Analysis of cartilage sequential extractions revealed differences
in the extractability of COMP between mice of all three
genotypes (Fig. 2B). For example, when analyzed under non-
reducing conditions a greater quantity of COMP was extracted in
buffers 1 and 2 from Matn3 V194D cartilage compared to both
Comp mutant mice and the wild type control (Fig. 2B, top panel).
The extraction of COMP from Comp T585M and Comp DelD469
mice was also increased in all buffers compared to the wild type
control, although the majority of COMP from both Comp T585M
and Comp DelD469 cartilage was extracted with buffer 3, which
was in contrast to Matn3 V194D cartilage. Finally, COMP
extracted from all mutant genotypes appeared larger in apparent
molecular weight compared to COMP extracted from wild type
cartilage under non-reducing conditions.
Interestingly, when protein samples were resolved under
reducing conditions Western blotting consistently showed the
complete absence of a single COMP fragment (,90 kDa) from
both Matn3 V194D and Comp DelD469 buffer 2 and buffer 3
extractions, which might represent full-length monomeric COMP
(Fig. 2B, bottom panel). Surprisingly, a number of higher
migrating bands were also detected by the COMP antibody
(between ,120–150 kDa) in all three genotypes and these
proteins were most prevalent in buffer 3 samples; however, the
nature of these bands remains unclear.
Wild type matrilin-3 is co-retained with mutant COMP in Comp
DelD469 chondrocytes
We hypothesized that the wild type matrilin-3 extracted in buffer 1
from Comp DelD469 and Comp T585M samples might represent
intracellular retained protein (Fig. 2B, top panel). We tested this
hypothesis by performing SDS-PAGE and Western blotting of
proteins isolated from the chondrocytes of 5-day-old mutant Comp
mice. This analysis confirmed that wild type matrilin-3 was co-
retained with mutant COMP in Comp DelD469 chondrocytes as a
tetramer (Fig. 3A, DelD469 in left panel). However, the level of co-
retention of wild type matrilin-3 in Comp DelD469 chondrocytes
was low in comparison to the retention of mutant matrilin-3 in
Matn3 V194D chondrocytes (Fig. 3A, compare V194D with
DelD469 in right panel). Furthermore, the retained wild type
Fig. 2. SDS-PAGE and Western blotting show genotype differences in the
extractability of matrilin-3 and COMP. Cartilage from wild type (WT) and
mutant (Matn3 V194D, Comp T585M and Comp DelD469) mice was extracted
in a series of three buffers (Buffer 1, 2 and 3). Proteins were separated by SDS-
PAGE under non-reducing conditions (unless stated otherwise) and analyzed by
Western blotting using antibodies specific to (A) matrilin-3 and (B) COMP.
The boxed area is shown at higher magnification in the bottom panel of A. Key:
615putative monomers; other putative oligomeric forms of proteins
(625dimers,635trimers,645tetramers); * denotes differences detected in
protein extraction profiles between mice of different genotypes; kDa5mass in
kilo Daltons.
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matrilin-3 was not present as high molecular weight aggregates in
the Comp DelD469 chondrocytes (not shown). In contrast, we were
not able to demonstrate the significant intracellular retention of
matrilin-3 in isolated Comp T585M chondrocytes (not shown),
which is consistent with the T585M form of mutant COMP being
efficiently secreted (Piro´g-Garcia et al., 2007). This latter finding
therefore suggests that increased matrilin-3 extraction with buffer 1
from Comp T585M is most likely due to disrupted anchoring/
interactions directly due to the T585M mutation in COMP.
Wild type COMP is co-retained in the chondrocytes of Matn3
V194D mice
Sequential protein extractions using buffers 1 and 2 indicated that
COMP was more readily extracted from Matn3 V194D cartilage
than wild type cartilage (Fig. 2B, bottom panel) and we
hypothesized that at least some of this COMP could represent
intracellular co-retained protein. We therefore analyzed proteins
extracted from isolated chondrocytes of Matn3 V194D cartilage
and free from any contaminating ECM. Wild type COMP was
detected within the chondrocytes of Matn3 V194D mice but at a
lower concentration than the mutant COMP detected in Comp
DelD469 chondrocytes (Fig. 3B). Under non-reducing conditions
the retained wild type COMP within Matn3 V194D chondrocytes
appeared as a single high molecular weight oligomeric form
(.250 kDa), which was consistent with a tetrameric form of
COMP (Fig. 3B, V194D in left panel). In contrast, several
oligomeric forms of mutant COMP were detected in Comp
DelD469 chondrocytes (Fig. 3B, DelD469 in left panel), which
could be resolved to monomers under reducing conditions
(Fig. 3B, right panel).
The adoption of a non-biased proteomic method to compare the
mouse cartilage protein extractions confirms genotype specific
differences in extractability
Given that it was not practical to analyze the extraction profiles
for every cartilage ECM component using our candidate
approach, we used a semi-quantitative proteomic method to
compare cartilage protein extractions in a global and non-biased
manner. For this investigation we used a method of in-gel trypsin
digestion of total proteins sequentially extracted from mouse
cartilage followed by LC-MS/MS analysis. In order to quantify
the relative levels of each protein identified we used spectral
counting, which has been established as a valid method for this
approach (Liu et al., 2004; Lundgren et al., 2010).
We compared the relative quantities of peptide spectra that
were detected by LC-MS/MS in wild type, Matn3 V194D, Comp
DelD469 and Comp T585M cartilage extracted by buffers 1, 2
and 3. The number of spectra identified for each protein were
compared between wild type and mutant genotypes using the beta
binomial test (Pham et al., 2010). Table 1 summarizes the total
number of proteins identified and the number of proteins that
were significantly changed in quantity between mutant and wild
type cartilage samples. The individual genes that encode the
relevant proteins were also subjected to DAVID functional
analysis in order to group proteins sharing common molecular
functions, cellular compartment or biological processes into
annotation clusters (see supplementary material Tables S1–S3 for
a list of all proteins significantly changed between mutant and
Fig. 3. Wild type matrilin-3 is co-retained with mutant COMP in Comp
DelD469 chondrocytes; wild type COMP is co-retained in the chondrocytes
of Matn3 V194D mice. Total protein lysate samples from isolated
chondrocytes of wild type (WT) and mutant (Matn3 V194D, Comp DelD469)
cartilage were separated by SDS-PAGE (reduced or non-reduced conditions)
and analyzed by Western blotting using antibodies specific to (A) matrilin-3 or
(B) COMP. Key:615putative monomers; putative oligomeric forms of
proteins (625dimers,635trimers,645tetramers,655pentamers);
rHMatn35recombinant full-length human matrilin-3 protein; kDa5mass in
kilo Daltons.
Table 1. Summary of the results from LC-MS/MS analysis of cartilage sequential extractions. The number of proteins identified
and the numbers of proteins significantly (P,0.05) increased/decreased in quantity in mutant samples compared with wild type controls
are indicated. The predicted number of results falsely identified as being significant by the beta-binomial test is indicated in brackets for
each comparison.
Genotype comparison Total # identified proteins
# proteins increased in mutant
genotype
# proteins decreased in mutant
genotype
Buffer 1 WT/V194D 393 (20) 21 24
WT/T585M 412 (21) 26 17
WT/DelD469 389 (20) 13 14
Buffer 2 WT/V194D 247 (12) 14 11
WT/T585M 280 (14) 14 11
WT/DelD469 247 (12) 14 9
Buffer 3 WT/V194D 516 (26) 29 21
WT/T585M 539 (27) 19 8
WT/DelD469 524 (26) 14 20
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wild type cartilage). In the first instance we chose to focus on
changes in the extraction profiles of cartilage ECM proteins.
The identification of common and discrete ECM disease
signatures in PSACH-MED cartilage
In order to identify both commonalities and differences in the
extraction profiles of structural ECM components from the three
different mouse models of PSACH-MED, we compared the
different MS-derived peptide profiles (unweighted spectra
number) (supplementary material Tables S1–S3) from mice of
all three genotypes (Fig. 4).
We noted common extraction profiles for two FACIT (fibril
associated collagens with interrupted triple helices) collagen
polypeptide chains; a1(XII) had decreased extractability in
Matn3 V194D and Comp T585M cartilage with buffer 2, whilst
a1(XIV) had decreased extractability in Matn3 V194D and Comp
DelD469 cartilage with buffers 1 and 2 (Fig. 4B). In contrast
a1(XIV) had increased extractability with buffer 3 from Comp
T585M cartilage (Fig. 4A).
Interestingly, in Comp T585M cartilage a1(IX) had marginally
decreased extractability in buffer 1, but considerably increased
extractability in buffer 3, which partially validated the
observations from the SDS-PAGE analysis (Fig. 1).
Surprisingly, the only significant change in type IX collagen
extractability in cartilage from Comp DelD469 mice was a slight
decrease in buffer 1; whilst a trend towards increased
extractability from buffer 3 samples was observed (P50.072),
even though there had been clear differences in SDS-PAGE
analysis of buffer 3 samples. Overall these observations suggest
that important interactions between COMP/matrilin-3 and
various FACIT collagens (types IX, XII and XIV) are disrupted
by the PSACH-MED mutations.
Tenascin X was noticeably less extractable from Comp
DelD469 cartilage (buffer 3), whilst Tenascin C was less
extractable from both Comp DelD469 and Matn3 V194D
cartilage (buffer 3) (Fig. 4B), suggesting an important role for
tenascin proteins in disrupted cell–matrix interactions within
these mutant cartilages. Finally, alpha-2-HS-glycoprotein (fetuin-
A), which has anti-calcification properties was less extractable
from both Matn3 V194D and Comp T585M cartilage (buffer 3)
(Fig. 4B).
In addition to the common profiles, we also noted unique ECM
extraction profiles for Matn3 V194D [matrilin-3 and decorin],
Comp T585M [a1(XI) and fibronectin] and Comp DelD469
[a1(VI), nidogen, thrombospondin-3 and tenascin X] mice,
suggesting that genotype specific differences in cartilage ECM
organization may also contribute to disease pathogenesis
(Fig. 4B).
In contrast to ECM proteins with decreased extractability, the
only common profile for increased extractability was for laminin
b2 in Matn3 V194D and Comp T585M cartilage (buffer 3),
whilst unique extraction profiles were noted for Matn3 V194D
[the SLRPs biglycan and osteomodulin and also a3(VI)], Comp
T585M [a6(VI), a1(IX) and a1(XIV)] and Comp DelD469 [a1(I)
and thrombospondin-4] cartilage samples (Fig. 4A).
Validation of ECM disease signatures by targeted Western blot
analysis
The spectral count data were verified using SDS-PAGE and
Western blot analyses of the cartilage protein extractions (Fig. 5).
For this validation of the LC-MS/MS approach we chose to focus
only on those ECM proteins that were commonly decreased in
extractability in more than one mouse model (e.g. types XIV and
XII collagen and tenascin C), or highly decreased in
extractability in a single mouse model (tenascin X in DelD469
COMP) (Fig. 2; supplementary material Tables S1–S3).
Following SDS-PAGE and Western blotting the band
intensities of proteins largely mirrored the spectral count data
derived from mass spectrometry analyses. For example, there was
a clear reduction in type XIV in protein samples from Matn3
V194D and Comp DelD469 cartilage (buffers 1 and 2) (Fig. 5A,
top panel) that closely correlated with the LC-MS/MS data
(supplementary material Tables S1–S3). Type XII collagen
reactivity was also correspondingly reduced in Matn3 V194D
samples (buffer 2), but it was also clear that there were other
changes in extractability using buffers 1 and 3 that had not been
detected using LC-MS/MS (Fig. 5A, bottom panel). In particular,
type XII collagen was less extractable in buffer 1 from the
cartilage of all mutant mice.
Analysis of tenascin C indicated that it was specifically the
largest protein isoform (I2: ,250 kDa) that was reduced in
Matn3 V194D and Comp DelD469 buffer 3 extractions when
compared with wild type and Comp T585M cartilages (Fig. 5B,
top panel). In addition, reduced extractability of tenascin X was
detected in cartilage from both the Comp T585M (buffer 3 only)
and Comp DelD469 (buffers 2 and 3) mice (Fig. 5B, bottom
panel) that was slightly different to spectral count data, which
Fig. 4. Genotype specific proteomic differences in mouse models of
PSACH-MED. Schematic showing cartilage ECM proteins that had either
significantly increased (A) or decreased (B) extractability in mouse models of
Matn3 V194D (V194D), Comp T585M (T585M) and Comp DelD469
(DelD469). Proteins with comparable extractability are shown in the
overlapping areas and the numbers in square brackets indicate which specific
buffers the proteins were extracted with.
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had only revealed a significant decrease in extractability of
tenascin X in Comp DelD469 buffers 3 samples. There was no
difference in the extraction of tenascin X from wild type and
Matn3 V194D cartilages, which was consistent with LC-MS/MS
data.
Proteomic validation of the intracellular ‘stress proteome’
disease signature in matrilin-3 V194D chondrocytes
In addition to identifying changes in the extractability of cartilage
ECM proteins we were also interested to know if the proteomic-
derived data correlated with the disease specific signatures
previously defined using gene expression studies. For this
comparison we compared the proteome from Matn3 V194D
cartilage (supplementary material Table S1) with previously
published gene array data for this mouse model (Nundlall et al.,
2010). The LC-MS/MS approach identified significantly
increased protein levels of several chaperones and foldases
including Grp94, Grp78 (BiP) and calreticulin (Calr), members of
the protein disulphide isomerase family (PDIA 3, 4 and 6) and
two novel ER-stress induced proteins, CRELD2 and Armet/
Manf. Significantly, all these proteins were previously shown to
be transcriptionally upregulated by microarray analysis (Nundlall
et al., 2010). Conversely, the extraction of proteins associated
with intracellular protein trafficking were significantly reduced in
Matn3 V194D samples (e.g. buffer 1: coatomer subunit beta
(COPB2), coatomer subunit delta (COPD) and GTPase Ran)
(supplementary material Table S1), which is consistent with the
intracellular retention of mutant matrilin-3 (Fig. 3). Furthermore,
the amount of proliferating nuclear cell antigen (PNCA) was
decreased in Matn3 V194D samples, concomitant with the
decreased rate of chondrocyte proliferation previously observed
in these mutant mice (Leighton et al., 2007).
Discussion
In this study we investigated the cartilage protein extraction
profile of three gene targeted mouse models of phenotypically-
related chondrodysplasias using both candidate and global
approaches in order to gain insight into ECM disorganization
and derive new perspectives on disease mechanisms and cartilage
degradation. This is the first time that such a dual approach has
been used to analyse cartilage from genetic models of human
ECM diseases.
SDS-PAGE and Western blot analysis of sequentially
extracted knee cartilage revealed genotype-specific differences
in the extraction of a number of proteins that included matrilin-1
to -4, COMP and type IX collagen, which are all known to
interact with each other (Budde et al., 2005; Fresquet et al., 2010;
Fresquet et al., 2007; Holden et al., 2001; Mann et al., 2004;
Wiberg et al., 2003). While we were unable to analyse the
insoluble material that remained following extraction of cartilage
tissue (and therefore could not quantify total differences in
protein abundance), our method was especially useful in allowing
us to identify subtle differences in the extraction of individual
protein oligomers that may not have been detected using other
methods. For example, two specific (hetero)oligomeric forms of
matrilin-1 were clearly absent from Matn3 V194D cartilage
extractions and given our previous data confirming the
intracellular co-retention of a proportion of wild type matrilin-1
with mutant matrilin-3 in the Matn3 V194D model (Bell et al.,
2012), we hypothesize that these matrilin-1 oligomers missing
from Matn3 V194D cartilage extractions represent matrilin-1/-3
hetero-oligomers, which we propose are present within the
heterogeneous disulphide bonded aggregates retained within the
ER of Matn3 V194D chondrocytes.
We detected a form of type IX collagen in sequential
extractions from Comp DelD469 and Comp T585M cartilage
that contained the a1(IX) NC4 domain and which corresponded
in size to the predicted molecular weight of the a1(IX) chain.
This form of type IX collagen was not extractable using the same
conditions from wild type or Matn3 V194D cartilage. Robust
microarray studies and immunohistochemical analyses have
previously demonstrated that there are comparable levels of
type IX collagen gene expression (Nundlall et al., 2010; Suleman
et al., 2012) and protein between the cartilage of wild type and all
three mutant mice (Leighton et al., 2007; Piro´g-Garcia et al.,
2007; Suleman et al., 2012) confirming that we had indeed
detected differences in extractability, rather than genotype
specific differences in the relative amounts of type IX collagen.
The results from LC-MS/MS analysis partially validated our
finding of increased a1(IX) collagen extraction from Comp
T585M and Comp DelD469 cartilage. For example, a significant
increase in the quantity of a1(IX) collagen was detected in Comp
T585M buffer 3 samples relative to wild type controls and a trend
towards an increase in a1(IX) collagen extraction was observed
in Comp DelD469 buffer 3 samples, but this did not reach
Fig. 5. Validation of proteomic analysis by SDS-PAGE and Western
blotting. SDS-PAGE and Western blot analysis of sequential cartilage
extractions for validation of the proteomic approach. Cartilage from wild type
(WT) and mutant (Matn3 V194D, Comp T585M and Comp DelD469) mice was
extracted in a series of three buffers (Buffer 1–3) and separated under reducing
conditions. (A) Analysis of types XII and XIV FACIT collagens, (B) analysis of
tenascin C and tenascin X. Results are shown for every buffer where protein
was detected by Western blot analysis. Mouse genotypes are indicated at the
top of each lane and the average numbers of matched peptide spectra detected
by LC-MS/MS analysis of the same cartilage extractions are shown at the
bottom of each lane. Key: I1 and I2 indicate the sizes of the different isoforms
of tenascin C; kDa5mass in kilo Daltons.
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statistical significance (WT spectra52 vs DelD469 spectra55;
P50.072; data not shown). However, in contrast to Western blot
analysis which detected no differences in the extraction of type
IX collagen from Comp DelD469 buffer 1 samples, LC-MS/MS
revealed a small decrease from similar extractions (WT
spectra52 vs DelD469 spectra50; P50.019). The small
number of matched spectra implies that this could potentially
represent a false positive, and therefore demonstrates the
importance of using complementary methods to gain an
accurate understanding of the cartilage proteome.
Types II, IX and XI collagen are highly cross-linked in mouse
cartilage by 3 weeks of age (Mendler et al., 1989); therefore, the
identification of extractable type IX collagen from Comp
DelD469 and Comp T585M cartilage suggests that it may be
less tightly integrated into the ECM of this abnormal cartilage.
This would have an impact upon the integrity of the cartilage
ECM and given the known function of type IX collagen in
cartilage and its influence on cartilage degradation when knocked
out (Fa¨ssler et al., 1994), may ultimately contribute to the early
onset OA seen in PSACH and MED patients.
We also identified differences in the molecular forms of
matrilin-3 that were extracted from Comp T585M and Comp
DelD469 cartilage by buffer 1. The matrilin-3 form that was
absent from Comp DelD469 samples was identified in wild type
(following longer exposure, data not shown) and Comp T585M
buffer 1 extractions and we hypothesize that this oligomer may
correspond to an N-terminally-cleaved form of tetrameric
matrilin-3 (Hills et al., 2007). This observation suggests a
possible difference in matrilin-3 processing in Comp DelD469
mice, the pathological consequence of which is not known.
Interestingly, matrilins are cleaved by ADAMT4 and -5 (Ehlen
et al., 2009) and it was postulated that the release of matrilin-3
from the matrix could in turn lead to further induction of pro-
inflammatory cytokines and proteases in chondrocytes (Klatt
et al., 2009) which could influence the occurrence of OA at later
stages of PSACH-MED.
The finding of an overall increase in the extractability of
matrilin-3 and COMP by buffer 1 in all three PSACH-MED
mouse models led us to consider that some of this protein could
represent intracellular retained material. Analysis of protein
lysates from isolated chondrocytes confirmed this hypothesis for
the Matn3 V194D and Comp DelD469 models, but more
importantly, it also confirmed that whilst both mutant proteins
are retained, only mutant V194D matrilin-3 is retained as a high
molecular weight covalently-linked aggregate (Bell et al., 2012).
This important observation demonstrates that the consequences
of the individual mutations on protein misfolding and retention/
accumulation differs between Matn3 V194D and Comp DelD469
and perhaps such differences begin to provide a molecular
explanation for why, in contrast to Matn3 V194D, Comp
DelD469 does not elicit a classical unfolded protein response
(Suleman et al., 2012).
We also used a proteomic method (LC-MS/MS spectral
counting) to compare cartilage sequential protein extractions in
a global non-biased manner. Our investigation made use of the
same cartilage extraction protocol used for Western blot analysis
and we detected a total of 957 unique proteins, which was
comparable with previous murine cartilage proteomic
investigations (Belluoccio et al., 2006; Pecora et al., 2007).
LC-MS/MS analysis of femoral cartilage extractions identified
significant changes in the extraction profiles of many proteins
including structural and non-structural ECM proteins, in addition
to proteins with known roles in protein folding and trafficking.
Among the most consistent findings was a relative decrease in
the amount of type XIV collagen extracted from Matn3 V194D
and Comp DelD469 cartilage compared with control and Comp
T585M samples. This decrease was evident through both spectral
counting and Western blotting approaches. Type XIV collagen
has recently been identified as a binding partner of COMP in
vitro (Agarwal et al., 2012), which suggests the possibility that a
disruption to the ECM by Matn3 V194D and Comp DelD469
mutations could affect type XIV collagen stability in the ECM by
altering direct binding between these proteins. This finding is
especially important given the role of type XIV in collagen
fibrillogenesis (Ansorge et al., 2009), the known disruption to
collagen fibrillogenesis caused by an MED-causing COMP
mutation (Hansen et al., 2011) and the previous finding of
altered collagen fibril morphology in Matn3 V194D, Comp
DelD469 and Comp T585M cartilages (Leighton et al., 2007;
Piro´g-Garcia et al., 2007; Suleman et al., 2012) (supplementary
material Fig. S3).
Interestingly, and somewhat in contrast to type XIV collagen,
there was decreased extraction of type XII collagen from Matn3
V194D and Comp T585M cartilages based on LC-MS/MS
analysis of buffer 2 samples. This observation was partially
validated by Western blotting, although the latter technique
identified additional differences that had not been detected by
LC-MS/MS. Recently, type XII collagen has been shown in vitro
to bind COMP via its collagenous domains (Agarwal et al.,
2012). Taken together these findings suggest a close functional
relationship between glycoproteins (matrilin-3 and COMP) and
FACIT collagens (Types IX, XII and XIV) in the chondrocyte
pericellular matrix and that disruptions to this network might be a
key disease trigger in cartilage degradation. Indeed, electron
microscopy of cartilage from the three mouse models has
previously demonstrated changes in the morphology of the
ECM (Leighton et al., 2007; Piro´g-Garcia et al., 2007; Suleman
et al., 2012). In particular, the collagen fibrils were more clearly
visible, suggesting that lower levels of fibril surface-associated
proteins were decorating individual collagen fibrils
(supplementary material Fig. S3). The common and discrete
disease signatures that we have identified in this study might
therefore explain these differences in the ‘cartilage phenotype’ of
these genetic mouse models of PSACH-MED.
A further difference in the extraction of a collagen-interacting
protein was observed in Comp DelD469 cartilage extractions,
where there was a significant decrease in the detection of tenascin X
compared with other genotypes. Tenascin X has only recently been
detected in cartilage (Wilson et al., 2012) and its knockout in mice
has been shown to cause a reduction in the collagen content of skin
(Mao et al., 2002). Furthermore, a wide variety of gene deletion
and truncating point mutations lead to tenascin X deficiency in skin
and recessive Ehlers–Danlos syndrome (Schalkwijk et al., 2001); a
disease characterized by hyperextensible skin, hypermobile joints
and tissue fragility. The knockout of tenascin X in mice, and its
deletion in humans, also causes alterations in muscle function
(Huijing et al., 2010; Voermans et al., 2011) that induces
histological features of a mild myopathy, which is also observed
in Comp mutant mice (Piro´g et al., 2010). Our finding provides
the first evidence of changes in the extractability of tenascin X
from the cartilage of a chondrodysplasia disease model. If the
reduced detection of tenascin X in cartilage were to extrapolate to
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other tissues where mutant COMP is expressed this could
potentially have pathological consequences and contribute to the
myotendonopathy associated with PSACH and MED (Piro´g and
Briggs, 2010).
A notable and potentially related observation was the
decreased detection of tenascin C in Matn3 V194D and Comp
DelD469 cartilage extractions. Tenascin C is an extracellular
glycoprotein involved in tissue injury/repair and is upregulated in
osteoarthritic cartilage, where tenascin C protein fragments are
believed to induce inflammatory mediators and ECM degradation
(Patel et al., 2011; Sofat et al., 2012). We found no evidence of
tenascin C fragmentation in Matn3 V194D and Comp DelD469
samples since the examination of matched peptides did not reveal
any genotype specific differences in sequence coverage (data not
shown). Interestingly, the decrease in tenascin C in Comp
DelD469 samples was accompanied by a corresponding
reduction in transforming growth factor beta induced protein
ig-h3 (Tgfbi) (supplementary material Table S3). Both of these
proteins have recently been proposed to contribute to TGFb1
signaling in early cartilage development (Wilson et al., 2012) and
alterations within TGFb1 signaling have been linked to
osteoarthritis (van der Kraan et al., 2010), whilst COMP itself
has recently been identified as a TGFb-responsive gene (Li et al.,
2011). The detrimental effects of chondrodysplasia-causing
mutations on the TGFb1 signaling pathway could therefore yield
pathological consequences for cartilage development and degen-
eration and potentially contribute to PSACH and MED disease
mechanisms. Alternatively, a decrease in TGFb1 signaling in
Comp DelD469 cartilage might form part of a feedback
mechanism to reduce the expression of mutant COMP.
The LC-MS/MS approach also validated the intracellular
disease signature of Matn3 V194D chondrocytes by confirming
increased protein levels of specific chaperones (Armet, Creld2,
Grp78, Grp94 and Calr) and foldases (PDIA 3, 4 and 6), that
have been previously shown to be highly upregulated at the
transcriptional level (Nundlall et al., 2010). These transcriptional
changes therefore support the proteomic analyses described in this
investigation.
Finally, recent studies have shown that numerous myogenic
genes (including MYH4) are expressed in articular cartilage, and
that changes in their expression constitutes a novel disease
signature in the STR/Ort murine model of OA (Poulet et al.,
2012). Interestingly, increased levels of myosin heavy
polypeptide 4 (MYH4) were detected in Matn3 V194D, Comp
T585M and Comp DelD469 cartilage (buffer 2) compared with
controls (supplementary material Tables S1–S3). These data
therefore provide new insight into the cartilage degeneration that
is associated with PSACH and MED and identifies areas for
further investigation.
To conclude, we have completed a proteomic analysis of
Matn3 V194D, Comp T585M and Comp DelD469 models of
chondrodysplasia and demonstrated that the mutation of matrilin-
3 or COMP can induce changes to the extractability of other
cartilage proteins confirming that there are disruptions to the
organization of the cartilage ECM. Whilst many of these changes
in ECM organization are genotype specific, there is also likely to
be a generalized disruption to cartilage integrity that ultimately
increases susceptibility to osteoarthritis, which is common to
both PSACH and MED. This semi-quantitative proteomic
approach, in combination with gene expression studies, also
provides a powerful tool to generate reference ‘-omics profiles’
that will help establish disease signatures in chondrodysplasias
that are also relevant to more common forms of joint
degeneration such as osteoarthritis. Defining these diseases
signatures is a prerequisite for the identification and validation
of potential biomarkers and future therapeutic applications.
Materials and Methods
Breeding of mice
Matn3 V194D, Comp DelD469 and Comp T585M mice were generated as
previously described (Leighton et al., 2007; Piro´g-Garcia et al., 2007; Suleman
et al., 2012) and control mice were of an equivalent mixed genetic background
(50% C57BL/6 and 50% 129Sv) to all mutant lines. Wild type and mutant mice
were used to provide cartilage for sequential protein extractions and chondrocytes
for Western blot analysis of intracellular proteins.
Cartilage protein extraction and chondrocyte isolation
Cartilage from knee joints and femoral heads were dissected from the hind limbs of
3-week-old mice and frozen at 280 C˚. Knee joints were dissected by removal of
the patella tendon and other connective tissue surrounding the joint using a scalpel,
followed by excision of all tissue proximal/distal to tibial/femoral epiphyseal
growth plates, respectively. Femoral heads were dissected by careful removal from
the acetabulum using a scalpel, followed by removal of all tissue distal to the
femoral head. Cartilage samples were thawed and sequentially extracted in buffer
1 (0.15 M NaCl, 50 mM Tris [pH 7.4]), buffer 2 (1 M NaCl 10 mM EDTA,
50 mM Tris [pH 7.4]) and buffer 3 (4 M GuHCl, 10 mM EDTA, 50 mM Tris
[pH 7.4]) as previously described (Nicolae et al., 2007). All buffers contained
2 mM phenylmethylsulfonyl fluoride and 2 mM N-ethylmaleimide protease
inhibitors. The supernatants from the extractions were ethanol precipitated, air
dried and resuspended as previously described (Nicolae et al., 2007). 20 ml aliquots
of each extraction were prepared and frozen at 280 C˚ prior to analysis by SDS-
PAGE. Costal chondrocytes were isolated as previously described (Nundlall et al.,
2010).
SDS-polyacrylamide gel electrophoresis and immunoblotting
Aliquots from three biological replicates per genotype (i.e. tissue extracts from 3
different mice) of knee or femoral head cartilage extractions and rib chondrocyte
preparations were thawed and separated on 4–13.5% and 4–12% SDS-
polyacrylamide gels respectively. When protein samples were reduced,
dithiothreitol (DTT) was added to a final concentration of 0.1 M and samples
were boiled at 90 C˚ for 5 min prior to loading. Proteins were transferred to
nitrocellulose membranes and uniform transfer was evaluated by ponceau staining
(supplementary material Fig. S4). The primary antibodies used were Matrilin-1
(Hauser and Paulsson, 1994), -2 (Piecha et al., 1999), -3 (reduced samples, R&D;
non-reduced samples (Klatt et al., 2000)), -4 (Klatt et al., 2001), COMP (reduced
samples, Genetex; non-reduced samples (DiCesare et al., 1994)), type IX collagen
NC4 domain (Budde et al., 2005), type XII collagen (Veit et al., 2006), type XIV
collagen (Ansorge et al., 2009), tenascin C (Sigma), tenascin X and decorin
(Wiberg et al., 2003). Membranes were incubated with either peroxidase-
conjugated or near-infrared fluorescently labeled secondary antibodies for 1 h.
Secondary antibodies used were peroxidase-conjugated swine anti-rabbit IgG
(Dako), donkey anti-mouse, anti-rabbit, anti-guinea pig and anti-goat IgGs (Licor).
Those blots incubated with fluorescently labeled antibodies were imaged using
the Odyssey system (Licor). Peroxidase-conjugated antibodies were detected using
3-amin-opthalhydrazide (1.25 mM), p-coumaric acid (225 mM) and 0.01% H2O2
then exposed to photographic film.
Mass spectrometry (MS) analysis of cartilage
20 ml aliquots of femoral head cartilage extracts were run on 4–12% SDS-
polyacrylamide gels for 4 mins (at 200 V). Total protein pools were excised from
the gel before being dehydrated, reduced, alkylated and washed. Samples were
then digested with trypsin overnight at 37 C˚ and analysed by LC-MS/MS using a
NanoAcquity LC (Waters, Manchester, UK) coupled to a LTQ Velos (Thermo
Fisher Scientific, Waltham, MA) mass spectrometer. Peptides were concentrated
on a pre-column (20 mm6180 mm i.d, Waters). The peptides were then separated
using a gradient from 99% A (0.1% formic acid in water) and 1% B (0.1% formic
acid in acetonitrile) to 25% B, in 45 min at 200 nL min21, using a
75 mm6250 mm i.d. 1.7 mM BEH C18, analytical column (Waters). Peptides
were selected for fragmentation automatically by data dependent analysis.
Bioinformatic processing of proteomics data
Data were interrogated using Mascot version 2.2 (Matrix Science, UK) against the
UniProt database (version 2011-05) with taxonomy of Mus musculus and the
following search parameters selected: fragment tolerance: 0.6 Da; parent
tolerance: 0.5 Da; fixed modifications allowed: +57 on C (carbamidomethyl),
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+16 on M (oxidation); max missed cleavages: 1. Mascot search results were
validated using Scaffold version 3.3.1 (Proteome Software, Portland, USA) to
assign confidence values to peptide/protein matches, where Peptide/Protein
Prophet algorithm confidence values of 0.7 and 0.99 were used respectively.
Identified proteins were defined as having a number of matched peptide spectra
>2, and the unweighted spectral count was used as a measure of quantification.
These parameters constrained the protein false discovery rate (FDR) to #0.2% in
all analyses. Three biological replicates were used in all experiments except for the
analysis of buffer 3 wild type samples, where two biological replicates were used
(as a result of sample failure in one replicate). The number of spectra identified for
each protein were compared between wild type and mutant genotypes using the
beta-binomial test in R (version 2.14.2, BetaBinomial package) (Pham et al.,
2010). A P-value,0.05 was considered significant. Lists containing the Uniprot
IDs of proteins that were significantly different in quantity between wild type/
mutant samples were analysed using The Database for Annotation, Visualization
and Integrated Discovery (DAVID) bioinformatics resource 6.7 (http://david.abcc.
ncifcrf.gov) (Dennis et al., 2003).
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